paclitaxel albumin-bound for Non-metastatic muscle-invasive bladder cancer

Inclusion criteria

• {"criterion_text":"- 18 years old or older"}
• {"criterion_text":"- Able and willing to give written informed consent"}
• {"criterion_text":"- For women of childbearing potential (WOCBP), study participants must use a contraceptive method that is highly effective (with a failure rate of < 1% per year) for at least 5 months after the last dose of study intervention. Men receiving any study drurg and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 6 months after the last dose of chemotherapy with cisplatin or nab-paclitaxel. The investigator or a designated associate is requested to advise the subject how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommend method (or combination of methods) as per standard of care. Acceptable methods are oral contraceptives, hormonal implants, hormonal patches, IDU, Diaphragm with spermicides, cervical cape with spermicide, and condom with spermicide"}
• {"criterion_text":"- Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment: a) Total bilirubin ≤1∙5 × the upper limit of normal (ULN). b) Alanine aminotransferase and aspartate aminotransferase ≤2 × ULN (≤5 × ULN for patients with liver involvement of their cancer). c) International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care.Platelet count ≥100 000/mm3, haemoglobin >9 g/dl, absolute neutrophil count >1,500/mm3. e) Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver involvement of their cancer). f) Creatinine clearance greater than 40 as evaluated by Cockcroft-Gault formula."}
• {"criterion_text":"- Histologic diagnosis of predominantly urothelial carcinoma of the bladder. Focal differentiation allowed other than small cell histology"}
• {"criterion_text":"- Stage T2-T3 N0M0 (AJCC TNM Staging System 8th ed. 2017) based on trans-urethral resection of bladder tumor (TURBT), CT or MRI imaging, +/- bimanual examination under anaesthesia (EUA)"}
• {"criterion_text":"- FDG-PET within 6 weeks from the start of treatments, showing no evidence of lymph nodes or metastatic disease"}
• {"criterion_text":"- Attempt of complete TURBT within 56 days (8 weeks) prior to the start of chemoradiation. If TURBT was performed > 8 weeks ago but a recent cystoscopy shows no residual disease, then a repeat TURBT is not necessary"}
• {"criterion_text":"- Life expectancy greater than 6 months"}
• {"criterion_text":"- ECOG performance status of 1 or better"}
• {"criterion_text":"- Another primary cancer is allowed only if treated with curative intent at least 3 years prior to enrolment without evidence of recurrence or if the untreated cancer is clinical indolent (e.g., lower risk prostate cancer)"}
• {"criterion_text":"- Patients must be considered able to tolerate systemic chemosensitizer combined with pelvic IMRT by the joint agreement of the participating radiation oncologist and medical oncologist."}

Exclusion criteria

• {"criterion_text":"- Prior systemic therapy for other urothelial tumours"}
• {"criterion_text":"- Received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti- PD-L1, anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-Cytotoxic Tlymphocyte- associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)."}
• {"criterion_text":"- Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial"}
• {"criterion_text":"- Active autoimmune disease that has required systemic treatment in past 2 years"}
• {"criterion_text":"- Received or will receive a live vaccine within 4 weeks prior to first dose of study drug except for vaccine against SARS-CoViD2. Influenza vaccination should be given during influenza season only (approximately October through May in the Northern Hemisphere and approximately April through September in the Southern Hemisphere). Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 28 days prior to randomization, during treatment or within 5 months following the last dose of nivolumab."}
• {"criterion_text":"- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan History of radiation pneumonitis in the radiation field (fibrosis) is permitted."}
• {"criterion_text":"- Active infection requiring IV systemic therapy"}
• {"criterion_text":"- Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible"}
• {"criterion_text":"- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate."}
• {"criterion_text":"- Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1, or anticipation of need for a major surgical procedure during the course of the study"}
• {"criterion_text":"- Prior allogeneic stem cell or solid organ transplant"}
• {"criterion_text":"- Prior RT to the pelvis"}
• {"criterion_text":"- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications"}
• {"criterion_text":"- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)"}
• {"criterion_text":"- Patients with active Hepatitis B virus (HBV) or Hepatitis C virus (HCV)"}
• {"criterion_text":"- Not willing or unable to sign a consent form."}
• {"criterion_text":"- Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug, whichever is longer, prior to enrolment."}
• {"criterion_text":"- Malignancies other than urothelial cancer within 3 years prior to Cycle 1, Day 1: a) Patients with localized lower risk prostate cancer (defined as Stage ≤T2b, Gleason score ≤ 7, and PSA at prostate cancer diagnosis ≤ 20 ng/mL [if measured]) treated with radical prostatectomy and without prostate-specific antigen (PSA) recurrence are eligible. b) Patients with lower risk prostate cancer (defined as Stage T1/T2a, Gleason score ≤ 7 and PSA ≤ 10 ng/mL) who are treatment-naive and undergoing active surveillance are eligible. c) Patients with malignancies of a negligible risk of metastasis or death (e.g., risk of metastasis or death <5% at 5 years) are eligible provided they meet all the following criteria: d) Malignancy treated with expected curative intent (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated surgically with curative intent) No evidence of recurrence or metastasis by follow-up imaging and any disease specific tumor markers"}
• {"criterion_text":"- Pre-existing medical conditions precluding treatment (e.g., previous history of immune-related adverse reactions, pneumonitis, colitis, etc.)"}
• {"criterion_text":"- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins"}
• {"criterion_text":"- History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study."}
• {"criterion_text":"- Active tuberculosis"}
• {"criterion_text":"- For women of childbearing potential (WOCBP), study participants must use a contraceptive method that is highly effective (with a failure rate of < 1% per year) for at least 5 months after the last dose of study intervention. Men receiving any study drurg and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 6 months after the last dose of chemotehrapy with cisplatin or nab-paclitaxel. Acceptable methods are oral contraceptives, hormonal implants, hormonal patches, IDU, Diaphragm with spermicides, cervical cape with spermicide, and condom with spermicide."}

Primary endpoints

• {"endpoint_text":"- The primary end point is one –year disease–free survival, which will be defined as the rate of survival free of recurrence in pelvic nodes or bladder (cis excluded), or appearance of distant metastasis with data censored at the first sign of disease or second primary tumor, or death","definition_or_measurement_approach":"Defined as the rate of survival free of recurrence in pelvic nodes or bladder (cis excluded), or appearance of distant metastasis with data censored at the first sign of disease or second primary tumor, or death (one-year disease-free survival)."}

Secondary endpoints

• {"endpoint_text":"- To describe the rate of patients who require salvage cystectomy","definition_or_measurement_approach":"Measured as the proportion (rate) of patients who undergo salvage cystectomy after trimodal therapy."}
• {"endpoint_text":"- To describe the rate of locoregional complete response","definition_or_measurement_approach":"Measured as the proportion achieving locoregional complete response (method of assessment not specified)."}
• {"endpoint_text":"- To describe the rate of locoregional disease-free survival","definition_or_measurement_approach":"Measured as locoregional disease-free survival rate (specific time-point not specified)."}
• {"endpoint_text":"- To describe the median disease-free survival","definition_or_measurement_approach":"Measured as median time to disease recurrence or death (method/statistics not specified)."}
• {"endpoint_text":"- To describe the median metastasis-free survival","definition_or_measurement_approach":"Measured as median time to development of distant metastasis (method/statistics not specified)."}
• {"endpoint_text":"- To describe the safety of the combination of nivolumab plus cisplatin and nab-paclitaxel with concomitant RT","definition_or_measurement_approach":"Assessed by reporting of adverse events and safety assessments (specific safety measures not detailed)."}
• {"endpoint_text":"- To describe the safety of nivolumab after RT","definition_or_measurement_approach":"Assessed by reporting of adverse events and safety assessments post-radiotherapy (specific measures not detailed)."}
• {"endpoint_text":"- Quality of life","definition_or_measurement_approach":""}

Italy

Earliest CTIS Part Ii Submission Date

11-10-2024

Latest Decision Or Authorization Date

26-11-2024

Processing Time Days

46

Number Of Sites

9

Number Of Participants

24

Primary sponsor

Full Name

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Italy

Third parties

• {"country":"","full_name":"Bristol Myers Squibbs s.r.l","duties_or_roles":"Source of monetary support","organisation_type":""}